Related Experiment Video

Updated: Aug 6, 2026

Isolation and Characterization of Neutrophils with Anti-Tumor Properties
10:15

Isolation and Characterization of Neutrophils with Anti-Tumor Properties

Published on: June 19, 2015

Fatal neutropenia associated with long-term tamoxifen therapy

V Miké, V E Currie, T S Gee

    Lancet (London, England)
    |August 20, 1994
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
    08:19

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

    Published on: July 20, 2019

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
    05:52

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

    Published on: May 12, 2023

    Related Experiment Videos

    Last Updated: Aug 6, 2026

    Isolation and Characterization of Neutrophils with Anti-Tumor Properties
    10:15

    Isolation and Characterization of Neutrophils with Anti-Tumor Properties

    Published on: June 19, 2015

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
    08:19

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

    Published on: July 20, 2019

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay
    05:52

    Neutrophil Lifespan Extension with CLON-G and an In Vitro Spontaneous Death Assay

    Published on: May 12, 2023

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

    Articles linked to this work by shared authors, journal, and citation graph.

    Practical guidelines for routine intensity-modulated radiotherapy verification: pre-treatment verification with portal dosimetry and treatment verification with in vivo dosimetry.

    The British journal of radiology·2010

    Outcomes research and the quality of health care: the beacon of an ethics of evidence.

    Evaluation & the health professions·1999

    Patients' pretreatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea.

    Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·1999

    Responsibility for clinical innovation. A case study in neonatal medicine.

    Evaluation & the health professions·1998

    Doctors and the health industry: a case study of transcutaneous oxygen monitoring in neonatal intensive care.

    Social science & medicine (1982)·1996

    Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients.

    Cancer chemotherapy and pharmacology·1994

    Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

    Lancet (London, England)·2026

    Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

    Lancet (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us